Results 51 to 60 of about 38,022 (310)

Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells

FEBS Open Bio, EarlyView.
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi, Zainab Quraishi, Shima Khezri Azizi Far, Madaleine Ward, Aidan Conway, Reem Abdulredha, Eman Mshari, Yousif A. Shamsaldeen   +7 more
wiley   +1 more source

Basal Insulin Use With GLP-1 Receptor Agonists [PDF]

Diabetes Spectrum, 2016
IN BRIEF The combination of basal insulin and a glucagon-like peptide 1 receptor agonist is becoming increasingly common and offers several potential benefits to patients with type 2 diabetes. Clinical studies have demonstrated improved glycemic control and low risks of hypoglycemia and weight gain with the combination, which provides a safe and ...
Anderson, Sarah L., Trujillo, Jennifer M.   +1 more
openaire   +2 more sources

A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction

Advanced Science, EarlyView.
Obesity involves chronic inflammation and mitochondrial dysfunction. This study identifies cytochrome P450 2E1 (CYP2E1) as a novel inflammatory target in adipose tissue. Its activity increases in obese mice and correlates with inflammation and mitochondrial impairment.
Jinhuan Qiu, Liyuan Gao, Liyang Wang, Xueke Wang, Lin Jia, Mengyan Deng, Liming Tang, Qiang Wen, Na Gao, Haiwei Xu, Hailing Qiao   +10 more
wiley   +1 more source

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Scientific Reports, 2019
Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases.
Mette Simone Aae Madsen, Jacob Bak Holm, Albert Pallejà, Pernille Wismann, Katrine Fabricius, Kristoffer Rigbolt, Martin Mikkelsen, Morten Sommer, Jacob Jelsing, Henrik Bjørn Nielsen, Niels Vrang, Henrik H. Hansen   +11 more
doaj   +1 more source

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Truncated glucagon-like peptide-1 and exendin-4 α-conotoxin pl14a peptide chimeras maintain potency and α-helicity and reveal interactions vital for cAMP signaling in vitro [PDF]

, 2016
Glucagon-like peptide-1 (GE P-1) signaling through the glucagon-like peptide 1 receptor (GLP-1R) is a key regulator of normal glucose metabolism, and exogenous GLP-1R agonist therapy is a promising avenue for the treatment of type 2 diabetes mellitus. To
Craik, David J., Derksen, David R., Edmonds, David J., Fairlie, David P., Griffith, David A., Liras, Spiros, Loria, Paula M., Mitchell, Justin M., Price, David A., Ruggeri, Roger B., Schroeder, Christina I., Swedberg, Joakim E.   +11 more
core   +1 more source

A Simplified Three‐Tailed N‐Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose‐Accumulated mRNA Delivery for Anti‐Obesity Therapy

Advanced Science, EarlyView.
This study develops an mRNA therapy encoding a long‐acting GLP‐1/FGF21 fusion protein. A three‐tailed ionizable lipid engineered three‐component lipid nanoparticle delivers the mRNA to inguinal adipose tissue. In obese mice, this targeted, dual‐hormone treatment potently reduces body weight, fat mass, presenting a localized strategy for metabolic ...
Bin Ma, Yunxuan Liu, Huijuan Zhang, Yian Fang, Yizhe Xue, Junsheng Xue, Ziqiong Jiang, Tianyan Zhou, Yanyun Hao, Fei Xie, Lei Miao   +10 more
wiley   +1 more source

Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study

Obesity Facts
Introduction: In Sweden, glucagon-like peptide-1 (GLP-1) receptor agonists are subsidized for diabetes indication but not for obesity. Unregulated off-label prescription of GLP-1 receptor agonists for obesity treatment may raise concerns about
Laura Pazzagli, Ylva Trolle Lagerros
doaj   +1 more source

Inhibition of Y1 receptor signaling improves islet transplant outcome [PDF]

, 2017
Failure to secrete sufficient quantities of insulin is a pathological feature of type-1 and type-2 diabetes, and also reduces the success of islet cell transplantation.
A Ali-Rachedi, A Thonpho, AD Nguyen, AG Nieuwenhuizen, AM Shapiro, AM Shapiro, American Diabetes, A., AR Saltiel, C Ammala, C Postic, C Ricordi, C Ricordi, CR Gustavsen, D Boey, D Boey, D Ize-Ludlow, DL Eizirik, DM Sousa, E Karra, G Bertrand, H Matsuda, H Yajima, HA Wieland, J Cantley, JM Sosenko, JY Kim, K Loh, K Yang, L Zhang, L Zhang, LA Selbie, M Jackerott, N Butta, O Idevall-Hagren, RA Stokes, RL Batterham, RP Robertson, S Kassis, S Seino, S Walters, T Yada, TL Belle van, TT Ngo, W Shao, Y Kashima, YC Shi, YC Shi   +46 more
core   +5 more sources